This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01489046
First received: December 7, 2011
Last updated: March 17, 2016
Last verified: March 2016
December 7, 2011
March 17, 2016
February 2011
March 2013   (Final data collection date for primary outcome measure)
  • Proportion of subjects with plasma HIV-1 RNA < 50 c/mL as measured by polymerase chain reaction (PCR) analyses [ Time Frame: Week 24 ]
  • Safety as measured by numbers of subjects with Serious Adverse Events (SAEs) and numbers of subjects with Adverse Events (AEs) leading to discontinuations [ Time Frame: Week 24 ]
Same as current
Complete list of historical versions of study NCT01489046 on ClinicalTrials.gov Archive Site
  • Proportion of subjects with plasma HIV-1 RNA < 50 c/mL as measured by PCR analyses [ Time Frame: Weeks 48 and 96 ]
  • Safety as measured by numbers of subjects with SAEs and numbers of subjects with AEs leading to discontinuation [ Time Frame: Weeks 48 and 96 ]
  • Changes from baseline in CD4+ T-cell counts [ Time Frame: Weeks 24, 48, and 96 ]
  • Numbers of subjects with virologic failure who exhibit genotypic substitutions in viral Ribonucleic acid (RNA) [ Time Frame: Weeks 24, 48, and 96 ]
  • Maximum observed concentration (Cmax) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ]
  • Time of maximum observed concentration (Tmax) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ]
  • Trough plasma concentration at 24 h post observed dose (Cmin) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ]
  • Trough plasma concentration pre-dose (C0) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ]
  • Area under the concentration-time curve in one dosing interval [AUC(0-24)] of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ]
  • Average steady-state plasma concentration (Css,avg) of BMS-986001 when co-administered with EFV and 3TC [ Time Frame: Week 24 ]
Same as current
Not Provided
Not Provided
 
Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose
The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects
Double Blind through Week 24. Partially Blind (to subjects, caregivers, Investigators) through Week 48.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
HIV-1 Infection
  • Drug: BMS-986001
    Capsules, Oral, 100 mg, Once daily, At least 48 weeks
  • Drug: BMS-986001
    Capsules, Oral, 200 mg, Once daily, At least 48 weeks
  • Drug: BMS-986001
    Capsules, Oral, 400 mg, Once daily, At least 48 weeks
  • Drug: Placebo matching with BMS-986001
    Capsules, Oral, 0 mg, Once daily, At least 48 weeks
  • Drug: Efavirenz
    Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
    Other Name: Sustiva®
  • Drug: Lamivudine
    Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
    Other Name: Epivir®
  • Drug: Tenofovir
    Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
    Other Name: Viread®
  • Experimental: Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine
    Interventions:
    • Drug: BMS-986001
    • Drug: Placebo matching with BMS-986001
    • Drug: Efavirenz
    • Drug: Lamivudine
  • Experimental: Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine
    Interventions:
    • Drug: BMS-986001
    • Drug: Placebo matching with BMS-986001
    • Drug: Efavirenz
    • Drug: Lamivudine
  • Experimental: Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine
    Interventions:
    • Drug: BMS-986001
    • Drug: Efavirenz
    • Drug: Lamivudine
  • Experimental: Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine
    Interventions:
    • Drug: Efavirenz
    • Drug: Lamivudine
    • Drug: Tenofovir
Gupta SK, McComsey GA, Lombaard J, Echevarría J, Orrell C, Avihingsanon A, Osiyemi O, Santoscoy M, Ray N, Stock DA, Joshi SR, Hanna GJ, Lataillade M. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. Lancet HIV. 2016 Jan;3(1):e13-22. doi: 10.1016/S2352-3018(15)00231-3. Epub 2015 Dec 12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
297
July 2014
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 18 years of age, (or minimum age as determined by local regulatory or as legal requirements dictate, whichever is higher)
  • Plasma HIV-1 RNA > 5000 copies/mL
  • Antiretroviral treatment-naive; defined as no current or previous exposure to > 1 week of an antiretroviral drug
  • CD4+ T-cell count > 200 cells/mm3

Exclusion Criteria:

  • Resistance to any of the study medications [Tenofovir Disoproxil Fumarate(TDF), Efavirenz (EFV), Lamivudine (3TC)] or to HIV Protease Inhibitors (PIs)
  • Contraindications to any of the study drugs
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Canada,   Chile,   Colombia,   France,   Hungary,   Mexico,   Peru,   South Africa,   Spain,   Thailand,   United States
Brazil,   Germany,   Poland,   Portugal
 
NCT01489046
AI467-003
2011-003329-89 ( EudraCT Number )
Yes
Not Provided
Not Provided
Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP